These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 956316)

  • 1. Simple gas chromatographic method with flame ionization detection for the determination of aldadiene in human urine.
    Fehér T; Bodrogi L; Váradi A
    J Chromatogr; 1976 Aug; 123(2):460-2. PubMed ID: 956316
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of a natural spirolactone derivative in man and animal.
    Genard P; Palem-Vliers M; Lomba-Pignon MR; Christiaens L; De Graeve J
    Arch Int Physiol Biochim; 1985 Sep; 93(3):255-6. PubMed ID: 2416293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 4. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic determination of spironolactone and its major metabolite canrenone in urine using ultraviolet detection and column-switching.
    Herráez-Hernández R; Soriano-Vega E; Campíns-Falcó P
    J Chromatogr B Biomed Appl; 1994 Aug; 658(2):303-10. PubMed ID: 7820258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous separation and rapid determination of spironolactone and its metabolite canrenone in different pharmaceutical formulations and urinary matrices by capillary zone electrophoresis.
    Li L; Huang Y; Zhao W; Zhang G; Zhang H; Chen A
    J Sep Sci; 2016 Jul; 39(14):2869-75. PubMed ID: 27257119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of partial least-squares regression for multicomponent determinations based on kinetic spectrofluorimetric data. Simultaneous determination of canrenone and spironolactone in urine.
    Hernández O; Martín E; Jiménez F; Jiménez AI; Arias JJ
    Analyst; 2000 Jun; 125(6):1159-65. PubMed ID: 10932858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gas chromatographic determination of levels of aldadiene in human plasma and urine following therapeutic doses of spironolactone.
    Chamberlain J
    J Chromatogr; 1971 Mar; 55(2):249-53. PubMed ID: 5547796
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples.
    Avataneo V; De Nicolò A; Rabbia F; Sciandra M; Tosello F; Cusato J; Perlo E; Fatiguso G; Allegra S; Favata F; Mulatero P; Veglio F; Di Perri G; D'Avolio A
    J Pharmacol Toxicol Methods; 2018; 94(Pt 2):29-35. PubMed ID: 30165207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
    Bartle WR; Coates PE; Fisher MM; Louman FJ
    Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone response related to plasma canrenone concentration [proceedings].
    Hettiarachchi J; Ramsay LE
    Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 18. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
    Chinn LJ; Brown EA; Mizuba SS; Karim A
    J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
    Tidd MJ; Collins WT; Chamberlain J
    J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.